Phase I dose-escalation study of F60008, a novel apoptosis inducer, in patients with advanced solid tumours

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Cancer cell resistance to chemotherapy is often linked to anti-apoptotic pathways like NF-kappaB.
• Inhibiting NF-kappaB activation presents a potential strategy to overcome chemotherapy resistance.
• F60008, a triptolide derivative, shows promise in activating apoptosis in human tumor cells.

Purpose of the Study:

• To conduct a Phase I and pharmacological study of F60008 in patients with advanced solid tumors.
• To evaluate the safety, tolerability, and pharmacokinetics of F60008 administered intravenously.
• To assess the potential of F60008 to overcome chemotherapy resistance by targeting apoptosis.

Main Methods:

• A Phase I clinical trial involving 20 patients with advanced solid tumors.
• Intravenous administration of F60008 weekly for 2 weeks every 3 weeks.
• Monitoring of adverse events, pharmacokinetic parameters, and markers of apoptosis (caspase-3 activity).

Main Results:

• A total of 35 cycles were administered; the most frequent side effects were mild anemia, fatigue, nausea, and gastrointestinal issues.
• Two lethal events occurred, associated with increased caspase-3 activity and apoptosis in immune cells.
• Pharmacokinetic studies revealed significant inter-individual variability, indicating F60008 is not an optimal triptolide derivative.

Conclusions:

• F60008 demonstrated induction of apoptosis in advanced solid tumors but exhibited significant toxicity and pharmacokinetic variability.
• The observed lethal events and high variability suggest F60008 requires further optimization or is not suitable for clinical development in its current form.
• Targeting NF-kappaB and apoptosis remains a valid strategy, but improved drug derivatives are needed to enhance efficacy and safety.